Literature DB >> 3042909

Psychiatric side effects during the treatment of Parkinson's disease.

H L Klawans1.   

Abstract

Dopaminergic agents including both levodopa and direct-acting agonists induce a variety psychiatric side-effects of which psychosis is the most significant. When this occurs early in the course of treatment, there is usually a history of prior psychotic illness. Chronic treatment can, however, elicit psychosis in individuals without such a history. The possible pathogenesis of this is reviewed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042909     DOI: 10.1007/978-3-7091-8954-2_11

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  5 in total

1.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.

Authors:  N Arai; M Isaji; M Kojima; E Mizuta; S Kuno
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.

Authors:  T Büttner; W Kuhn; T Müller; F L Welter; J Federlein; K Heidbrink; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease.

Authors:  E Stuebner; E Vichayanrat; D A Low; C J Mathias; S Isenmann; C A Haensch
Journal:  Clin Auton Res       Date:  2015-02-18       Impact factor: 4.435

Review 5.  Parkinson's disease: medical treatment of moderate to advanced disease.

Authors:  Oksana Suchowersky
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.